Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study

Yu-Fen Tsai, Ching-I Yang, Jeng-Shiun Du, Ming-Hui Lin, Shih-Hao Tang, Hui-Ching Wang, Shih-Feng Cho, Yi-Chang Liu, Yu-Chieh Su, Chia-Yen Dai, Hui-Hua Hsiao, Yu-Fen Tsai, Ching-I Yang, Jeng-Shiun Du, Ming-Hui Lin, Shih-Hao Tang, Hui-Ching Wang, Shih-Feng Cho, Yi-Chang Liu, Yu-Chieh Su, Chia-Yen Dai, Hui-Hua Hsiao

Abstract

Background: Hepatitis B virus (HBV) reactivation with a hepatitis flare is a common complication in lymphoma patients treated with immunotherapy and/or chemotherapy. Anti-HBV prophylaxis is suggested for non-Hodgkin lymphoma (NHL) patients undergoing rituximab therapy, even those with resolved HBV infection. Since anti-HBV prophylaxis for patients with resolved HBV infection is not covered by national health insurance in Taiwan, a proportion of these patients receive no prophylaxis. In addition, late HBV reactivation has emerged as a new issue in recent reports, and no consensus has been reached for the optimal duration of antiviral prophylaxis. Thus, the aim of our study was to investigate the incidence and outcomes of HBV reactivation in NHL patients in a real-world setting and to study the frequency of late HBV reactivation.

Materials: Non-Hodgkin lymphoma patients who received rituximab and/or chemotherapy at our institute between January 2011 and December 2015 and who were hepatitis B surface antigen (HBsAg)- or hepatitis B core antibody (HBcAb)-positive were reviewed retrospectively.

Results: A total of 388 patients were screened between January 2011 and December 2015. In total, 196 patients were excluded because HBsAg was not assessed, HBcAb was negative or not assessed, or they were not treated with immunosuppressive therapy. Finally, the retrospective study included 62 HBsAg-positive NHL patients and 130 NHL patients with resolved HBV infection (HBsAg-negative and HBcAb-positive). During a median 30.5-month follow-up period, seven patients experienced HBV reactivation, five of whom had a hepatitis flare. The incidence of HBV reactivation did not significantly differ between the HBsAg-positive patients and the resolved HBV infection population without anti-HBV prophylaxis (4.8% vs. 3.1%, P = 0.683). All patients with HBV reactivation were exposed to rituximab. Notably, late HBV reactivation was not uncommon (two of seven patients with HBV reactivation events, 28.6%). Hepatitis B virus reactivation did not influence the patients' overall survival. An age ≥65 years and an advanced disease stage were independent risk factors for poorer overall survival.

Conclusion: The incidence of HBV reactivation was similar between the HBsAg-positive patients with antiviral prophylaxis and the resolved HBV infection population without anti-HBV prophylaxis. All HBV reactivation events occurred in NHL patients exposed to rituximab. Late reactivation was not uncommon. The duration of regular liver function monitoring for more than 1 year after immunosuppressive therapy or after withdrawal of prophylactic antiviral therapy should be prolonged. Determining the exact optimal duration of anti-HBV prophylaxis is warranted in a future prospective study for NHL patients treated with rituximab-containing therapy.

Keywords: HBV reactivation; HBsAg-positive; Non-Hodgkin lymphoma; Resolved HBV infection; Rituximab.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2019 Tsai et al.

Figures

Figure 1. Flowchart of patient selection.
Figure 1. Flowchart of patient selection.
HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; H. pylori, Helicobacter pylori.
Figure 2. Kaplan–Meier survival curve of overall…
Figure 2. Kaplan–Meier survival curve of overall survival for all NHL patients.

References

    1. Castelli R, Ferraris L, Pantaleo G, Lambertenghi Deliliers G, Cicardi M. High rate of hepatitis B viral breakthrough in elderly non-Hodgkin lymphomas patients treated with Rituximab based chemotherapy. Digestive and Liver Disease. 2016;48(11):1394–1397. doi: 10.1016/j.dld.2016.08.113.
    1. Chen W-C, Cheng J-S, Chiang P-H, Tsay F-W, Chan H-H, Chang H-W, Yu H-C, Tsai W-L, Lai K-H, Hsu P-I, Huang Y-H. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy. PLOS ONE. 2015;10(6):e0131545. doi: 10.1371/journal.pone.0131545.
    1. Chen FW, Coyle L, Jones BE, Pattullo V. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver International. 2013;33(8):1203–1210. doi: 10.1111/liv.12154.
    1. Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. Journal of Medical Virology. 2016;88(6):1010–1017. doi: 10.1002/jmv.24423.
    1. Dong H-J, Ni L-N, Sheng G-F, Song H-L, Xu J-Z, Ling Y. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: a meta-analysis. Journal of Clinical Virology. 2013;57(3):209–214. doi: 10.1016/j.jcv.2013.03.010.
    1. Evens AM, Jovanovic BD, Su Y-C, Raisch DW, Ganger D, Belknap SM, Dai M-S, Chiu B-CC, Fintel B, Cheng Y, Chuang S-S, Lee M-Y, Chen T-Y, Lin S-F, Kuo C-Y. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology. 2011;22(5):1170–1180. doi: 10.1093/annonc/mdq583.
    1. Gust ID. Immunisation against hepatitis B in Taiwan. Gut. 1996;38(Suppl 2):S67–S68. doi: 10.1136/gut.38.Suppl_2.S67.
    1. Hsiao L-T, Chiou T-J, Gau J-P, Yang C-F, Yu Y-B, Liu C-Y, Liu J-H, Chen P-M, Tzeng C-H, Chan Y-J, Yang M-H, Huang Y-H. Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-Hodgkin lymphoma patients: a large cohort retrospective study. Medicine (Baltimore) 2015;94(32):e1321. doi: 10.1097/MD.0000000000001321.
    1. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312(23):2521–2530. doi: 10.1001/jama.2014.15704.
    1. Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, Kim JS, Eom HS, Lee JH, Zhu J, Chang KM, Reksodiputro AH, Tan D, Goh YT, Lee J, Intragumtornchai T, Chng WJ, Cheng AL, Lim ST, Suh C, Kwong YL, Kim WS. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. European Journal of Cancer. 2013;49:3486–3496. doi: 10.1016/j.ejca.2013.07.006.
    1. Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, Zoulim F, Tacke F. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Journal of Hepatology. 2017;67(2):370–398. doi: 10.1016/j.jhep.2017.03.021.
    1. Lee I-C, Huang Y-H, Chu C-J, Lee P-C, Lin H-C, Lee S-D. Hepatitis B virus reactivation after 23 months of rituximab-based chemotherapy in an HBsAg-negative, anti-HBs-positive patient with follicular lymphoma. Journal of the Chinese Medical Association. 2010;73(3):156–160. doi: 10.1016/S1726-4901(10)70031-9.
    1. Li H-R, Huang J-J, Guo H-Q, Zhang X, Xie Y, Zhu H-L, Zhai L-Z, Pu X-X, Huang Y, Guo C-C, Lin T-Y. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. Journal of Viral Hepatitis. 2011;18(12):877–883. doi: 10.1111/j.1365-2893.2010.01386.x.
    1. Liu WP, Wang XP, Zheng W, Ping LY, Zhang C, Wang GQ, Song YQ, Zhu J. Hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy in patients with diffuse large B cell lymphoma. Leukemia and Lymphoma. 2016;57(6):1355–1362. doi: 10.3109/10428194.2015.1116121.
    1. Matsubara T, Nishida T, Shimoda A, Shimakoshi H, Amano T, Sugimoto A, Takahashi K, Mukai K, Yamamoto M, Hayashi S, Nakajima S, Fukui K, Inada M. The combination of anti-HBc and anti-HBs levels is a useful predictor of the development of chemotherapy-induced reactivation in lymphoma patients with resolved HBV infection. Oncology Letters. 2017;14(6):6543–6552. doi: 10.3892/ol.2017.7012.
    1. Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of occult hepatitis B virus infection 27 months after the end of chemotherapy including rituximab for malignant lymphoma. Internal Medicine. 2017;56(15):1967–1971. doi: 10.2169/internalmedicine.56.8233.
    1. Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, Hotta M, Yoshimura H, Ishii K, Ito T, Nomura S. Delayed HBV reactivation in rituximab-containing chemotherapy: how long should we continue anti-virus prophylaxis or monitoring HBV-DNA? Leukemia Research. 2016;50:46–49. doi: 10.1016/j.leukres.2016.09.014.
    1. Persico M, De Marino F, Russo GD, Morante A, Rotoli B, Torella R, De Renzo A. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood. 2002;99(2):724–725. doi: 10.1182/blood.V99.2.724.
    1. Seto W-K, Chan TSY, Hwang Y-Y, Wong DK-H, Fung J, Liu KS-H, Gill H, Lam Y-F, Lie AKW, Lai C-L, Kwong Y-L, Yuen M-F. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. Journal of Clinical Oncology. 2014;32(33):3736–3743. doi: 10.1200/JCO.2014.56.7081.
    1. Sung J-L. Hepatitis B virus infection and its sequelae in Taiwan. Gastroenterologia Japonica. 1984;19(4):363–366. doi: 10.1007/BF02779126.
    1. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, Brown RS, Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD, 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560–1599. doi: 10.1002/hep.29800.
    1. Yamada T, Nannya Y, Suetsugu A, Shimizu S, Sugihara J, Shimizu M, Seishima M, Tsurumi H. Late reactivation of hepatitis B virus after chemotherapies for hematological malignancies: a case report and review of the literature. Internal Medicine. 2017;56(1):115–118. doi: 10.2169/internalmedicine.56.7468.
    1. Yeo W, Chan TC, Leung NWY, Lam WY, Mo FKF, Chu MT, Chan HLY, Hui EP, Lei KIK, Mok TSK, Chan PKS. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Journal of Clinical Oncology. 2009;27(4):605–611. doi: 10.1200/JCO.2008.18.0182.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅